key: cord-1020767-g15s47au authors: Choudhary, Shalki; Sharma, Kajal; Singh, Harpreet; Silakari, Om title: The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options date: 2020-12-02 journal: Microb Pathog DOI: 10.1016/j.micpath.2020.104673 sha: 080c0ca4108fde121322f9d885101824ea48e566 doc_id: 1020767 cord_uid: g15s47au COVID-19, caused by SARS-CoV-2, emerged as the deadliest outbreak that has now become a serious health issue to mankind. Activation of inflammatory signaling pathways and cytokine storm are crucial factors that lead to acute respiratory distress syndrome (ARDS) in COVID-19 patients. Excessive secretion of pro-inflammatory cytokines and chemokines leads to the dysregulation of the innate immune system. The cytokine storm attracts many inflammatory cells that infiltrate into the lung tissues and ultimately cause immune damage. In addition to the dysregulation of the immune system, dysfunction of the renin-angiotensin system (RAS) due to the downregulation of ACE2 is also associated with the mortality of COVID-19 patients. Both the mechanisms are directly or indirectly associated with cytokine storm that promotes vascular hyperpermeability, vascular edema leading to hypercoagulation and hence multiorgan damage. As of now, there is no specific treatment available for COVID-19, but scientists have purposed several treatment options including cytokine inhibitors, JAK inhibitors, immunomodulators, plasma therapy, etc. In this article, we provide the detailed mechanism of occurrence of SARS-CoV-2 induced inflammatory storm and its connection with the pre-existing inflammatory conditions. Possible treatment options to cope up with the severe clinical manifestations of COVID-19 are also discussed. Cytokines are cell signaling molecules, the term "cytokine" is derived from two words "cyto" 19 means cell and "kinos" means movement. The massive activation of the immune system leads to 20 a severe complication called cytokine storm or cytokine release syndrome (CRS) involving 21 immense and uncontrolled release of pro-inflammatory cytokines and other inflammatory cells 22 which causes excessive inflammation. Cytokine storm, generated due to the activation of various 23 inflammatory signaling pathways, is reported to be the foremost reason for mortality in COVID- Iron metabolism plays a significant role in supporting the innate immune system to fight against 7 attacking microorganisms (bacteria, viruses, or fungi). As a response to viral infections, the 8 innate immune system control iron metabolism. Adequate iron levels within the host cells are 9 required for viral replication. Subsequently, the innate immune system will respond by 10 diminishing the bioavailability of iron to restrict viral replication. Helicases of SARS-CoV-2 11 require ATP hydrolysis for replication which needs the presence of iron, making it deprive of 12 iron will help in combating the virus. This mechanism would also result in anemia, which, in 13 turn decrease the oxygen delivery to the tissue and may lead to the development of multi-organ 14 failure. There are various biomarkers associated with iron metabolism including haemoglobin, ferritin, hepcidin, transferrin, soluble transferrin receptor, haptoglobin, unsaturated iron-binding extremely high levels of ferritin (> 3000 ng/ml) seem to be associated with increased mortality in 10 a dose-response manner. Additionally, hepcidin, an 84-amino-acid long prepropeptide hormone 11 is also a major regulator of iron metabolism, modifying intracellular and extracellular iron 12 concentration. It performs two important functions: the first one is to store iron into the cell to 13 allow cellular multiplication and DNA and RNA synthesis; the second one is its antimicrobial 14 action by depriving the pathogen of iron for replication [57] . Hepcidin acts by inhibiting the 15 activity of the cellular iron exporter ferroportin (via its internalization and eventual degradation), 16 which is involved in iron transport, thus reduces extracellular iron bioavailability. HAMP 17 (hepcidin antimicrobial protein) is the gene responsible for hepcidin production that may be 18 found predominantly in the liver, but also the brain, lungs, body fat, and other organs. The 19 production of hepcidin seems to be influenced by many factors with a complex up and down-20 regulation mechanism. The factors that appeared to upregulate the production of hepcidin are 21 Hereditary Hemochromatosis Gene (HFE), Transferrin Receptors (TfR1 and TfR2) Fenton reactions and reactive nitrogen species (RNS) and reactive sulfur species (RSS). The 20 mitochondria are the core organelle of ROS generation. Increased generation of ROS contributes 21 to intra-mitochondrial and extra-mitochondrial damage resulting in microbiota dysbiosis and 22 platelet dysfunction. Mitochondrial damage results in the release of contents including proteins, 23 lipids and DNA "spinoffs" that further exacerbate the inflammatory response in COVID-19 24 disease. The upregulation of mitochondrial genes and genes that respond to oxidative stress has 25 been reported to facilitate the interplay between inflammation and oxidative stress. Inflammatory 26 mediators and immunocytes activate intracellular pathways that result in mitochondrial 27 alteration. Pro-inflammatory cytokines such as TNF-α induces a calcium-dependent increase in 28 mitochondrial ROS. Furthermore, IFN-γ was found to upregulate genes inducing mitochondrial 29 ROS generation. IL-6 and IL-10 were found to modulate mitochondrial ROS generation by 30 directly modulating the activity of the electron transport chain. It was reported that mitochondrial 1 IL-6 and TNF-α inhibit mitochondrial oxidative phosphorylation and subsequent ATP 2 production and induces mitochondrial ROS production in the cell. This can lead to 3 permeabilization of mitochondrial membrane, altered mitochondrial dynamics, and eventually, 4 result in cell death (apoptosis). Furthermore, hyperferritinemia disrupts mitochondrial 5 homeostasis driving mitochondrial respiration from aerobic into an anaerobic state. Decreased 6 mitochondrial respiration results in abnormal metal distribution including manganese, copper 7 and zinc. Consequently, reduced mitochondrial manganese can result in mitochondrial 8 dysfunction, possibly due to diminished activity of mitochondrial manganese-dependent 9 superoxide dismutase, an enzyme that prevents free radical generation in mitochondria. All these 10 pieces of evidence explain the potential role of the inflammatory signals in propagating a series 11 of events that aggravate mitochondrial oxidative damage and contribute to other serious systemic 12 alterations including coagulopathy, ferroptosis, and microbial dysbiosis [63]. 13 14 15 From the findings that SARS-CoV-2 nucleic acid has been detected in the stool of patients with 16 COVID-19 pneumonia, it is well indicated that SARS-CoV-2 can colonize in the gastrointestinal 17 tract, which would disturb gut microbiota. The interaction between microbiota and mitochondria 18 tends to appear primarily through endocrine, immune, and humoral links. The commensal gut 19 microbiota affects mitochondrial functions related to energy production, mitochondrial 20 biogenesis, redox balance, and inflammatory cascades. Gut commensal microbiota produces 21 metabolites including the secondary bile acids and beneficial short-chain fatty acids (SCFA) such 22 as N-butyrate that reduce oxidative stress and subsequent ROS production, suggesting it as a Certain clinical studies report some individuals to have inborn errors of type I IFN immunity. The type I IFN immunity in such individuals is impaired by defects of TLR3, Interferon to the delayed release of IFN-λ (which act as anti-viral) in asthmatic patients increase the risk of 28 asthma exacerbation [77] [90]. In a study conducted on asthmatic patients of different age 29 groups, it was observed that the patients of age group 18-49 years are at high risk of SARS-CoV-and the symptoms are somewhat similar to COVID-19 i.e. dry cough, shortness of breath making 1 it quite difficult to differentiate between COVID-19 and asthma. Asthma exacerbations are 2 associated with bronchial hyperactivity and eosinophilic inflammation. It is highly recommended 3 to continue with the current asthma regimen as it helps in reducing the severity of the infection. in sepsis, but a broad investigation is required to confirm these findings. Vitamin C is a safe and Cyclosporine therapy during the COVID-19 pandemic is not a reason for concern. Journal of the Asthma and COVID-19: is asthma a risk factor for severe outcomes? Asthma and COVID-19 Diabetes is a risk factor for the 6 progression and prognosis of COVID-19. Diabetes/metabolism research and reviews COVID-19 pandemic, coronaviruses, and diabetes mellitus Covid-19 and diabetes mellitus: unveiling the interaction of two 11 pandemics. Diabetes/metabolism research and reviews COVID-19 revisiting inflammatory pathways of 13 arthritis COVID-19 with rheumatic diseases: a 15 report of 5 cases What is the true incidence of COVID-19 in 17 patients with rheumatic diseases? Annals of the rheumatic diseases COVID-19 and psoriasis: should we fear for 19 patients treated with biologics? Dermatologic therapy Novel 21 coronavirus disease (COVID-19) and biologic therapy in psoriasis: infection risk and patient Effective treatment of severe COVID-19 12 patients with tocilizumab Patients With High Dose of Ulinastatin COVID-19 16 pneumonia treated with Sarilumab: a clinical series of eight patients Use of siltuximab 19 in patients with COVID-19 pneumonia requiring ventilatory support Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory 22 distress syndrome, and hyperinflammation: a retrospective cohort study Canakinumab in a subgroup of patients with COVID-19. The Lancet Rheumatology COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment COVID-19: a case for inhibiting IL-17? Treating COVID-19 with chloroquine Observational study of 3 hydroxychloroquine in hospitalized patients with Covid-19 Successful use of methylprednisolone for 6 treating severe COVID-19 Cyclosporine A: a valid candidate to treat COVID-19 8 patients with acute respiratory failure? JAK inhibition with methotrexate as treatment for COVID-19 is a 10 double-edged sword Colchicine as a possible therapeutic option in COVID-19 infection Clinical trials on drug repositioning for COVID-19 treatment Imiquimod as a potential treatment for COVID-19 The safety of baricitinib in patients with rheumatoid arthritis. Expert 19 opinion on drug safety JAK 21 inhibition as a new treatment strategy for patients with COVID-19 Ongoing clinical trials for the management of the COVID-19 1 pandemic Ustekinumab poised to enter the psoriasis market Therapeutic monoclonal antibodies approved by FDA in 2015 COVID-19: Melatonin as a potential 7 adjuvant treatment Impact of corticosteroid therapy on 11 outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic 12 review and meta-analysis Effectiveness of 14 glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a 15 randomized controlled trial A retrospective cohort study of 17 methylprednisolone therapy in severe patients with COVID-19 pneumonia. Signal transduction 18 and targeted therapy High-dose methotrexate with leucovorin rescue for severe COVID-19: An immune 21 stabilization strategy for SARS-CoV-2 induced 'PANIC'attack Early 1 safety indicators of COVID-19 convalescent plasma in 5,000 patients. The Journal of clinical 2 investigation Treatment of 5 critically ill patients 4 with COVID-19 with convalescent plasma Potential of 6 regulatory T-cell-based therapies in the management of severe COVID-19 Regulatory T cells for 9 treating patients with COVID-19 and acute respiratory distress syndrome: two case reports. 10 Annals of Internal Medicine Perspectives on 12 monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 13 (COVID-19) Monoclonal antibodies for prevention and treatment 15 of COVID-19 A human 17 monoclonal antibody blocking SARS-CoV-2 infection VEGF) as a Vital Target for Brain Inflammation during the COVID-19 Outbreak VEGF-D: a novel biomarker for detection The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Author(s) have no such conflict of interest to declare J o u r n a l P r e -p r o o f